Crescent Biopharma, Inc.
Market Cap
$616.45M
P/E Ratio
-1.75
EPS
$-12.81
Dividend Yield
0.00%
52-Week Range
$8.72 — $29.00
Volume
273.63K
Avg Volume
231.72K
Beta
1.03
Get alerted when CBIO hits your target price.
Free — enter your email to get started
P/E (TTM)
-1.75
Forward P/E
—
PEG Ratio
-0.13
P/S (TTM)
14.16
P/B (TTM)
10.92
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-1.22%
ROA (TTM)
-0.59%
ROIC
—
Gross Margin
0.96%
Operating Margin
-3.40%
Net Margin
—
Debt/Equity
0.01
Current Ratio
6.56
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
+0.20%
EPS Growth (5Y)
+0.13%
Sales Growth (3Y)
-0.93%
Sales Growth (5Y)
-0.74%
EPS Est (This Year)
$-5.34
EPS Est (Next Year)
$-4.10
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$2.05
Price Target Range
Consensus Target: $32.00(43.0% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
27.56M
Float
22.10M
Free Float %
80.20%
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
2014-01-10
Employees
41
CEO
Joshua T. Brumm
Index Membership
—
Website
https://crescentbiopharma.com
Crescent Biopharma, Inc. (CBIO) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $616.45M, a P/E ratio of -1.75, CBIO is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare CBIO against other stocks using dozens of fundamental and technical filters.
Crescent Biopharma, Inc. (CBIO) has a trailing twelve-month (TTM) P/E ratio of -1.75. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Crescent Biopharma, Inc. (CBIO) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Crescent Biopharma, Inc. (CBIO) has a market capitalization of $616.45 million, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.